Kevin Vela

Kevin joined the Cell and Gene Therapy (CGT) Catapult in October 2022 as Collaborations Manager, where he leads the creation and establishment of impactful collaborations and multi-party consortia that deliver innovative solutions to key challenges in the CGT sector. His orchestration of collaborations spans across the entire CGT value-chain, with a particular focus on championing the adoption and use of automation and digital technologies to drive innovation in Research and Development, Manufacturing and Supply of CGTs.

Prior to joining CGT Catapult, Kevin worked as a data scientist in Orchard Therapeutics’ manufacturing division, focusing on the development, scale-up, tech transfer and validation of manufacturing processes for clinical and commercial-grade gene therapy programs. He has also served as a scientist at Imperial College London researching the use of lipid nanoparticles for cancer therapeutics and as a business development manager for the Worldfolio.

Kevin holds a BSc in Biotechnology and a Masters in the development and commercialisation of Cell and Gene Therapies from Imperial College London.